JAK1 mutations are the most frequent in T-cell acute lymphoblastic leukemia (6.5–27%), followed by B-cell acute lymphoblastic leukemia (1.5%),218–220 indicating that JAK inhibitors are necessary to treat hematological disease. Here, JAK1 is linked to hematologic disorder.